The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer

Lung Cancer

Volumn 19, Issue 3, 1998, Pages 167-177

  Kiffer, John D ^a   Berlangieri, Salvatore U ^a   Scott, Andrew M ^b   Quong, George ^a   Feigen, Malcolm ^a   Schumer, Wendy ^a   Clarke, C Peter ^a   Knight, Simon R ^a   Daniel, Fredy J ^a  

^a AUSTIN HEALTH   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Co registration; Lung cancer; Radiotherapy planning; Simulator images

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; FLUORINE;

ARTICLE; CANCER REGRESSION; DIAGNOSTIC VALUE; HUMAN; ISOTOPE LABELING; LUNG CANCER; LUNG SCINTISCANNING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR LOCALIZATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; LUNG TUMOR; RETROSPECTIVE STUDY; SCINTISCANNING;

FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031596296     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00086-X     Document Type: Article

References (27)

1. Boland GW, Goldberg MA, Lee MJ et al. Indeterminate adrenal mass in patients with cancer. Radiology. 194:1995;131-134.
2. Chin R Jr., Ward R, Keyes JW et al. Mediastinal staging of non-small cell lung cancer with positron emission tomography. Am J Respir Crit Care Med. 152:1995;2090-2096.
3. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: a comparative risk - benefit analysis. Chest. 108:1995;441-446.
4. 18F-FDG PET. J Thorac Cardiovasc Surg. 110:1995;130-139.
5. Glasgow GP, Purdy JA. External beam dosimetry and treatment planning. Perez CA, Brady LW Principles and Practice of Radiation Oncology. 1992;208-245 Lippincott, Philadelphia.
6. 18F]-FDG PET. Radiology. 184:1992;441-444.
7. 18F-FDG PET. J Nucl Med. 37:1996;943-949.
8. Hebert ME, Lowe VJ, Hoffman JM, Patz EF, Anscher MS Positron emission tomography in the pre-treatment evaluation and follow-up of non-small cell lung cancer patients treated with RT: preliminary findings. Am J Clin Oncol. 19:1996;416-421.
9. Hubner KF, Buonocore E, Singh SK, Gould HR, Cotten DW Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med. 20:1995;293-298.
10. Kessler ML, Pitluck S, Petti P, Castro JR Integration of multimodality imaging data for RT treatment planning. Int J Radiat Oncol Biol Phys. 21:1991;1653-1667.
11. Kubota K, Matsuzawa T, Fujiwara T Differential diagnosis of lung tumour with positron emission tomography: a prospective study. J Nucl Med. 31:1990;1927-1933.
12. Munley MT, Scarfone MS, Marks LB et al. Multimodality nuclear medicine imaging in radiation treatment planning for lung cancer: challenges and prospects. Int J Radiat Oncol Biol Phys. 36:1996;188.
13. Nolop KB, Rhodes CG, Brudin LH Glucose utilization in vivo by human pulmonary neoplasms. Cancer. 60:1987;2682-2689.
14. Oliver TW, Bernardino ME, Miller JE, Mansour R, Greene D, Davis WA Isolated adrenal masses in non-small cell bronchogenic carcinoma. Radiology. 153:1984;217-218.
15. Pathmaraj K, Berlangieri SU, Scott AM et al. Validation of landmark based registration of thoracic FDG-PET to CT in patients with lung cancer. Aust New Zealand J Med. 26:1996;737.
16. 18F-FDG in patients with bronchogenic carcinoma. Chest. 108:1995;1617-1621.
17. Rege SD, Hoh CK, Glaspy JA et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer. 72:1993;82-90.
18. Reinig JW, Doppman JL, Dwyer AL Adrenal masses differentiated by MR. Radiology. 158:1986;81-84.
19. Sasaki M, Ichiya Y, Kuwabara Y et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med. 23:1996;741-747.
20. 18F]-FDG in brain abscess: a PET study. J Comput Assisted Tomogr. 14:1990;486-487.
21. Sazon DA, Santiago SM, Soo Hoo GW et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med. 153:1996;417-421.
22. Scott AM, Macapinlac H, Zhang J et al. Clinical applications of fusion imaging in oncology. Nucl Med Biol. 21:1994;775-784.
23. 18F]-FDG uptake in abdominal abscesses: a PET study. J Comput Assisted Tomogr. 13:1989;829-831.
24. Valk PE, Pounds TR, Hopkins DM et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 60:1995;1573-1581.
25. Wahl RL, Quint LE, Cieslack RD, Aisen AM, Koeppe RA, Meyer CR Antimetabolic tumour imaging: fusion of FDG-PET with CT or MRI to localize foci of increased activity. J Nucl Med. 34:1993;1190-1197.
26. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: preliminary prospective evaluation. Radiology. 191:1994;371-377.
27. Yu JN, Fahey FH, Gage HD et al. Intermodality, retrospective image registration in the thorax. J Nucl Med. 36:1995;2333-2338.